BFEC
BPMC

Benjamin F. Edwards & Company’s Blueprint Medicines BPMC Stock Holding History

Benjamin F. Edwards & Company’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-100
Closed -$5K – 1820
2022
Q2 		$5K Sell
100
-256
-72% -$15K ﹤0.01% 1524
2022
Q1 		$23K Sell
356
-550
-61% -$39.5K ﹤0.01% 1200
2021
Q4 		$97K Buy
906
+150
+20% +$15.7K ﹤0.01% 885
2021
Q3 		$78K Buy
+756
New +$70.4K ﹤0.01% 914
2019
Q4 		– Sell
-40
Closed -$3K – 1866
2019
Q3 		$3K Hold
40
– – ﹤0.01% 1669
2019
Q2 		$4K Hold
40
– – ﹤0.01% 1661
2019
Q1 		$3K Hold
40
– – ﹤0.01% 1557
2018
Q4 		$2K Hold
40
– – ﹤0.01% 1589
2018
Q3 		$3K Buy
+40
New +$2.78K ﹤0.01% 1468

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Benjamin F. Edwards & Company's BPMC Position: Q3 2022 in Review

Benjamin F. Edwards & Company sold out of Blueprint Medicines (BPMC) in Q3 2022, closing a stake of 100 shares — an estimated $5K sold.

Benjamin F. Edwards & Company first reported a position in BPMC in Q3 2018 and held it in 9 quarters. The position peaked at $97K in Q4 2021. 240 funds tracked by Wall St. Rank hold BPMC as of Q3 2022.

  • Benjamin F. Edwards & Company reported no remaining Blueprint Medicines position as of Q3 2022 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 100 Blueprint Medicines shares in Q3 2022, an estimated $5K.
  • Benjamin F. Edwards & Company first reported a position in Blueprint Medicines in Q3 2018 and held it in 9 quarters.
  • Benjamin F. Edwards & Company's Blueprint Medicines position peaked at $97K in Q4 2021.
  • 240 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2022.

Based on Benjamin F. Edwards & Company's 13F filing for Q3 2022, filed 28 Oct 2022.